Chuanlian Chenpi Powder is a veterinary-grade botanical active pharmaceutical ingredient manufactured from the dried mature pericarp of Citrus reticulata Blanco. Unlike concentrated Chenpi extracts, the product retains the native pericarp matrix after drying, milling, and particle-size classification. The resulting powder is intended for further pharmaceutical processing into tablets, injections, capsules, oral powders, granules, feed premixes, and liquid solutions. It is not a finished dose form and is not supplied as a sterile or depyrogenated substance. Manufacturer documentation identifies two controlled-mesh grades: CL-CP-VG-80, with a nominal sieve aperture of 180 µm, and CL-CP-VG-120, with a nominal aperture of 125 µm. The lot designation should be confirmed against the current certificate of analysis because particle-size specifications influence dispersion, blend uniformity, and extraction efficiency in downstream operations. The primary standardisation marker for Chuanlian Chenpi Powder is hesperidin, a flavanone glycoside that is determined by high-performance liquid chromatography using the current Chinese Pharmacopoeia monograph for Citri Reticulatae Pericarpium. The manufacturer applies a minimum acceptance criterion of 3.5% hesperidin on the dried basis. This value is a marker of botanical identity and consistency; it does not by itself define the full pharmacological profile of the material. The powder also contains native pectin-like polysaccharides, polymethoxyflavones including nobiletin and tangeretin, and volatile oil constituents associated with the citrus pericarp. These accompanying components influence granulation behavior, capsule fill, extraction yield, and the clarity of liquid preparations. For this reason, the material is handled as a multi-constituent botanical API rather than as a single-marker synthetic entity. Because the source material is agricultural, lot-to-lot variation can be larger than that of synthetic APIs. Control therefore requires simultaneous testing of identity, moisture, ash, heavy metals, microbial burden, and particle-size distribution. The most significant processing constraints are low bulk density, fibrous flow, partial water insolubility, and sensitivity of the botanical constituents to high pH and prolonged heating. These constraints define the downstream routes suitable for the material and separate it from directly compressible synthetic compounds.

What Limits Specification Compliance in Botanical Veterinary APIs?

The acceptance profile for Chuanlian Chenpi Powder combines botanical identification, marker quantification, elemental impurity screening, and microbial enumeration. Because raw dried peel can vary with cultivar, growing region, harvest year, and storage temperature, the specification is intended to reject lots with excessive moisture, mineral contamination, or unacceptable microbial load. Moisture control is particularly important because water accelerates the hydrolysis of flavonoid glycosides and supports mould growth in milled botanical solids. Total ash and acid-insoluble ash detect soil, sand, and mineral contamination introduced during drying or handling. Heavy metal and microbial limits are aligned with the current Chinese Pharmacopoeia botanical requirements and with relevant ISO methods for Salmonella detection. The table below presents the core specification profile that governs lot release. The density and particle-size parameters are characteristic of the two controlled-mesh grades and are used for scale-up calculations rather than as absolute safety limits.

Quality parameter	Method or standard	Acceptance limit
Description	Visual inspection	Light brown to brown powder; characteristic citrus odour; no visible foreign matter
Identification	CP 2020 thin-layer chromatography and HPLC	Positive for hesperidin and dried tangerine peel reference
Moisture	CP 2020 method 0832	≤ 13.0%
Total ash	CP 2020 method 2302	≤ 5.0%
Acid-insoluble ash	CP 2020 method 2302	≤ 1.0%
Hesperidin marker	CP 2020 HPLC	≥ 3.5% on dried basis
Lead	ICP-MS / CP 2020	≤ 5 mg/kg
Arsenic	ICP-MS / CP 2020	≤ 2 mg/kg
Cadmium	ICP-MS / CP 2020	≤ 1 mg/kg
Mercury	ICP-MS / CP 2020	≤ 0.2 mg/kg
Total aerobic microbial count	CP 2020 method 1105	≤ 10⁴ CFU/g
Moulds and yeasts	CP 2020 method 1105	≤ 10² CFU/g
Escherichia coli	CP 2020 method 1106	Absent in 1 g
Salmonella	ISO 6579-1:2017 / CP 2020	Absent in 25 g
Particle size D90, CL-CP-VG-80	Laser diffraction, ISO 13320:2020	≤ 180 µm
Particle size D90, CL-CP-VG-120	Laser diffraction, ISO 13320:2020	≤ 125 µm
Bulk density	USP <616>	0.35–0.55 g/mL, typical
Tapped density	USP <616>	0.50–0.75 g/mL, typical

The physical density values are typical and may vary with moisture and milling intensity. A lot with bulk density below 0.35 g/mL may require higher granulation liquid volumes, while a lot above 0.55 g/mL may have undergone excessive fines retention or moisture uptake. Published data for every particle-size subclass of this specific product is limited, and the current certificate of analysis should be verified before setting silo capacity, bin blender fill, or tablet press feed shoe settings.

High-Shear Wet Granulation, Dry Compression Risk, and Premix Homogeneity

Direct compression of this fibrous botanical powder is rarely successful without substantial excipient modification. The native powder exhibits low bulk density, high fines content, and variable cohesion, which produces die-filling inconsistency on high-speed rotary tablet presses. Die-fill failure appears as tablet weight variation exceeding ±5% or as capping and lamination when compression force is increased. In rotary press trials, a target hardness of 50–80 N for 12 mm flat-faced bevel-edge tablets is achievable after wet granulation, but direct compression of the powder alone at the same hardness usually increases friability above the common acceptance criterion of 1.0%. The preferred solid-dosage route is high-shear wet granulation. A representative formulation contains 60–70 wt% Chuanlian Chenpi Powder, 20–30 wt% microcrystalline cellulose, 5–10 wt% pregelatinized starch, and 2–5 wt% crospovidone. Povidone K30 in purified water at 3–5% w/v is added until the wet mass reaches 12–15% w/w moisture. The endpoint is judged by impeller torque plateau rather than by fixed volume; on production-scale high-shear granulators, overwetting produces a dense wet mass that can stall the impeller and block the 1.5 mm wet-mill screen, while underwetting yields weak granules and excessive fines. After granulation, the wet mass is milled through a 1.5 mm mesh, dried at 55–60 °C in a fluid-bed dryer to 2–4% w/w moisture, and sized through a 0.8 mm screen. Hard gelatin capsules filled with such granules should maintain granulate moisture below 4% to avoid shell embrittlement or softening. The final blend is typically lubricated with magnesium stearate at 0.5–1.0% w/w and compressed or filled within 4 h to limit lubricant overmixing. Flow characterization by USP <616> methods gives a Hausner ratio in the region of 1.35–1.50 and a Carr index of 25–35%, indicating poor to passable flow for the unmilled powder. Addition of colloidal silicon dioxide at 0.5–1.0 wt% or dry mixing with a free-flowing carrier improves flow but can reduce hesperidin uniformity if over-sheared. This behavior differs from that of synthetic hesperidin, which is crystalline and typically flows more readily. For feed premixes and oral powders, segregation is controlled by particle-size matching and layering. The Chuanlian powder is first combined with a portion of carrier, passed through a 500 µm screen, and mixed for 10 min in a double-cone or ribbon blender at 60–70% nominal capacity. Blend uniformity is assessed by sampling from the top, middle, and bottom of the blender; the relative standard deviation of hesperidin content should remain below 5.0%. If the final premix is diluted into complete feed, the inclusion rate is determined by the target species, feed intake, and regulatory status of the botanical in the intended market. Injectable formulations require a separate quality paradigm. Chuanlian Chenpi Powder is not sterile and is not depyrogenated; it must not be introduced directly into parenteral lines. For aqueous injection development, the powder is usually extracted with purified water or a water-ethanol mixture at 50–60 °C for 2–4 h, clarified by centrifugation, and filtered through 0.45 µm followed by 0.22 µm membrane filters. The resulting filtrate is filled into depyrogenated vials and terminally autoclaved at 121 °C for 15 min, or sterilized by filtration when autoclave exposure causes visible aggregation. Pectin-like polysaccharides can form haze or flocculent precipitate after terminal sterilization, especially at low pH or during cold storage. Membrane capacity should be evaluated because polysaccharides and residual fine pericarp particles can rapidly block sterilizing-grade filters. Endotoxin control for injectable-grade aqueous extracts should meet ≤0.5 EU/mg by limulus amebocyte lysate testing according to USP <85>. Hydroalcoholic extraction at 40–60% v/v ethanol increases hesperidin recovery but requires vacuum concentration below 60 °C to avoid caramelization of residual sugars and oxidation of polymethoxyflavones. If ethanol is used, residual ethanol in the finished solution should be controlled according to VICH GL18 or USP <467>, depending on the target market.

When Hydroalcoholic Extraction Is Required for Solutions

For oral solutions and drinking-water products, direct addition of the powder to water does not produce a true solution because hesperidin and the principal polymethoxyflavones are only sparingly water-soluble. The powder can be formulated as an oral suspension with xanthan gum at 0.2–0.5% w/v or sodium carboxymethyl cellulose at 0.5–1.0% w/v. Potassium sorbate at 0.1–0.2% w/v may be used as a preservative. The suspension is homogenized with a rotor-stator mixer at 10–15 m/s for 10–15 min and stored at 2–8 °C. Sedimentation is controlled by viscosity, but excessive thickening agent increases dosing syringe backpressure and slows ejection. If a clear oral solution is required, the botanical material is extracted before final formulation. Typical extraction ratios range from 1:8 to 1:12 powder to solvent, using ethanol at 40–60% v/v. Maceration or percolation at 50–60 °C for 2–4 h extracts hesperidin and accompanying flavonoids; the extract is then concentrated under vacuum below 60 °C. The concentrate is diluted into the final aqueous vehicle at a pH between 4.0 and 6.0. Alkaline conditions should be avoided during heating because they accelerate flavonoid oxidation and produce colour instability. This extraction route removes much of the insoluble fiber and pectin-like polysaccharide fraction; therefore, the final liquid is no longer a full-herb powder dosage form but a concentrated Chenpi liquid extract. Storage of the dry powder should be in tightly closed containers at or below 25 °C and 60% RH. Prolonged exposure to humidity above 60% RH can increase moisture beyond the acceptance limit and produce caking. The product should not be blended with strong oxidizing agents, and contact with open steam lines or hot metal surfaces above 80 °C should be avoided to limit volatile oil loss and discolouration.

Differences from Coarse Peel, Concentrated Extract Powders, and Synthetic Hesperidin

Unprocessed dried Chenpi slices differ from Chuanlian Chenpi Powder mainly in particle control and specification compliance. Whole or coarse-cut peel requires in-house milling, may carry variable moisture, ash, and microbial counts, and can segregate during dry mixing. The controlled-mesh powder is supplied with a lot-specific certificate of analysis and is suited to metered blending and standardized granulation. Compared with concentrated Chenpi extract powders, the full-herb powder retains native polysaccharides and fiber but contains a lower hesperidin mass fraction per unit weight. Concentrated extract powders may provide higher marker loading per gram and often flow better after spray-drying, but they are more hygroscopic and may require anticaking agents. Compared with synthetic hesperidin, the botanical powder contains accompanying flavonoids and volatile oil constituents that are absent from single-marker crystalline material. The presence of these additional constituents may influence palatability and compatibility in feed matrices, but the exact contribution to efficacy in target veterinary species requires formulation-specific data and is not defined by single-marker standardisation.

Product form	Marker content	Typical processing behaviour	Principal limitation
Chuanlian Chenpi Powder	≥ 3.5% hesperidin	Wet granulation; controlled mesh	Not aqueous-soluble; not sterile
Concentrated Chenpi extract powder	Typically 10–20% hesperidin, supplier-dependent	Spray-dried; may direct compress	Hygroscopic; loses native fiber and volatile oil
Unprocessed dried peel pieces	Variable, may fall below 3.0%	In-house milling; high segregation risk	Uncontrolled ash, moisture, and microbial load
Synthetic hesperidin	≥ 95.0%	Crystalline; direct compression feasible	Lacks polysaccharide and flavonoid matrix

For a tablet line that requires direct compression, concentrated extract powder or synthetic hesperidin may be operationally simpler; however, the full-herb powder is retained when the formulation objective is to deliver the native pericarp matrix. The choice should be governed by the target product that the veterinary marketing authorisation recognizes, the required extraction profile, and the process capability of the manufacturing site.